These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30657103)

  • 41. Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
    Saeed A; Khan M; Elmamoun M; Brady M; Morrissey S; Fraser AD
    Rheumatol Int; 2012 May; 32(5):1305-9. PubMed ID: 21286722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.
    Bodur H; Yurdakul FG; Ataman S; Cay HF; Gurer G; Capkin E; Sezer İ; Duruoz MT; Melikoglu MA; Rezvani A; Yagci I; Gogus F; Kamanli A; Akgul O; Cevik R
    Clin Rheumatol; 2022 Jul; 41(7):2053-2063. PubMed ID: 35353263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.
    Lorenzin M; Ortolan A; Frallonardo P; Oliviero F; Punzi L; Ramonda R
    BMC Musculoskelet Disord; 2015 Jul; 16():166. PubMed ID: 26205000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.
    Baraliakos X; Haibel H; Fritz C; Listing J; Heldmann F; Braun J; Sieper J
    Arthritis Res Ther; 2013; 15(3):R67. PubMed ID: 23786760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis.
    Konsta M; Bamias G; Tektonidou MG; Christopoulos P; Iliopoulos A; Sfikakis PP
    Rheumatology (Oxford); 2013 Mar; 52(3):448-51. PubMed ID: 23204549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.
    Heldmann F; Baraliakos X; Kiltz U; Brandt J; van der Horst-Bruinsma IE; Landewé R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Gaston H; Gruenke M; Witt M; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Braun J
    Clin Exp Rheumatol; 2016; 34(2):184-90. PubMed ID: 27049733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis.
    Deodhar A; Yu D
    Semin Arthritis Rheum; 2017 Dec; 47(3):343-350. PubMed ID: 28551170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
    Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
    Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.
    Ruwaard J; l'Ami MJ; Marsman AF; Kneepkens EL; van Denderen JC; van der Horst-Bruinsma IE; Nurmohamed MT; Wolbink G
    Scand J Rheumatol; 2018 Mar; 47(2):122-126. PubMed ID: 28745108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Systemically Used Anti-Tumor Necrosis Factor-α Medication on the Corneal Epithelium and Stroma of Patients with Ankylosing Spondylitis.
    Arikan S; Gokmen F; Ersan I; Akbal A; Resorlu H; Gencer B; Ali Tufan H; Kara S
    Ocul Immunol Inflamm; 2017 Apr; 25(2):223-228. PubMed ID: 26731089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
    Wang Y; Wang H; Jiang J; Zhao D; Liu Y
    Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
    Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
    Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
    Murray C; Fearon C; Dockery M; Moran D; Heffernan E; Fitzgerald O; Veale DJ; Harty L
    Ir Med J; 2018 Oct; 111(9):820. PubMed ID: 30556668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.